|
1
|
Hwang SY, Danpanichkul P, Agopian V, Mehta
N, Parikh ND, Abou-Alfa GK, Singal AG and Yang JD: Hepatocellular
carcinoma: Updates on epidemiology, surveillance, diagnosis and
treatment. Clin Mol Hepatol. 31 (Suppl):S228–S254. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vogel A, Meyer T, Sapisochin G, Salem R
and Saborowski A: Hepatocellular carcinoma. Lancet. 400:1345–1362.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marrero JA, Kulik LM, Sirlin CB, Zhu AX,
Finn RS, Abecassis MM, Roberts LR and Heimbach JK: Diagnosis,
staging, and management of hepatocellular carcinoma: 2018 practice
guidance by the American association for the study of liver
diseases. Hepatology. 68:723–750. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lou J, Li Y, Liang K, Guo Y, Song C, Chen
L, Wang L, Wang F, Zhang L, Chen X, et al: Hypofractionated
radiotherapy as a salvage treatment for recurrent hepatocellular
carcinoma with inferior vena cava/right atrium tumor thrombus: A
multi-center analysis. BMC Cancer. 19:6682019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reig M, Forner A, Rimola J, Ferrer-Fàbrega
J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V,
Salem R, et al: BCLC strategy for prognosis prediction and
treatment recommendation: The 2022 update. J Hepatol. 76:681–693.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Singal AG, Llovet JM, Yarchoan M, Mehta N,
Heimbach JK, Dawson LA, Jou JH, Kulik LM, Agopian VG, Marrero JA,
et al: AASLD practice guidance on prevention, diagnosis, and
treatment of hepatocellular carcinoma. Hepatology. 78:1922–1965.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Llovet JM, Castet F, Heikenwalder M, Maini
MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX and Finn RS:
Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol.
19:151–172. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kokudo T, Hasegawa K, Matsuyama Y,
Takayama T, Izumi N, Kadoya M, Kudo M, Kubo S, Sakamoto M,
Nakashima O, et al: Liver resection for hepatocellular carcinoma
associated with hepatic vein invasion: A Japanese nationwide
survey. Hepatology. 66:510–517. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ichida A, Kokudo T, Shimada S, Hatano E,
Kubo S, Kato Y, Ishikawa Y, Mori A, Baba H, Matsuyama Y, et al:
Liver resection for hepatocellular carcinoma with tumor thrombus in
the inferior vena cava or right atrium: A large-scale multicenter
survey conducted in Japan. Ann Surg. 278:e549–e555. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Psilopatis I, Damaskos C, Garmpi A,
Sarantis P, Koustas E, Antoniou EA, Dimitroulis D, Kouraklis G,
Karamouzis MV, Vrettou K, et al: FDA-approved monoclonal antibodies
for unresectable hepatocellular carcinoma: What do we know so far?
Int J Mol Sci. 24:26852023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ahn JC, Tran NH and Yang JD: Systemic
therapy in advanced hepatocellular carcinoma. Clin Mol Hepatol.
29:516–519. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Llovet JM, De Baere T, Kulik L, Haber PK,
Greten TF, Meyer T and Lencioni R: Locoregional therapies in the
era of molecular and immune treatments for hepatocellular
carcinoma. Nat Rev Gastroenterol Hepatol. 18:293–313. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
European Association for the Study of the
Liver, . EASL clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol. 69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Naugler WE, Alsina AE, Frenette CT,
Rossaro L and Sellers MT: Building the multidisciplinary team for
management of patients with hepatocellular carcinoma. Clin
Gastroenterol Hepatol. 13:827–835. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen ZH, Wang K, Zhang XP, Feng JK, Chai
ZT, Guo WX, Shi J, Wu MC, Lau WY and Cheng SQ: A new classification
for hepatocellular carcinoma with hepatic vein tumor thrombus.
Hepatobiliary Surg Nutr. 9:717–728. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xia Y, Zhang J and Ni X: Diagnosis,
treatment and prognosis of hepatocellular carcinoma with inferior
vena cava/right atrium tumor thrombus. Oncol Lett. 20:1012020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Y, Yuan L, Ge RL, Sun Y and Wei G:
Survival benefit of surgical treatment for hepatocellular carcinoma
with inferior vena cava/right atrium tumor thrombus: Results of a
retrospective cohort study. Ann Surg Oncol. 20:914–922. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wakayama K, Kamiyama T, Yokoo H, Kakisaka
T, Kamachi H, Tsuruga Y, Nakanishi K, Shimamura T, Todo S and
Taketomi A: Surgical management of hepatocellular carcinoma with
tumor thrombi in the inferior vena cava or right atrium. World J
Surg Oncol. 11:2592013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang X, Yang C, Zhang S, Geng H, Zhu AX,
Bernards R, Qin W, Fan J, Wang C and Gao Q: Precision treatment in
advanced hepatocellular carcinoma. Cancer Cell. 42:180–197. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shen KY, Zhu Y, Xie SZ and Qin LX:
Immunosuppressive tumor microenvironment and immunotherapy of
hepatocellular carcinoma: Current status and prospectives. J
Hematol Oncol. 17:252024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang C, Zhang H, Zhang L, Zhu AX, Bernards
R, Qin W and Wang C: Evolving therapeutic landscape of advanced
hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol.
20:203–222. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maker AV, Attia P and Rosenberg SA:
Analysis of the cellular mechanism of antitumor responses and
autoimmunity in patients treated with CTLA-4 blockade. J Immunol.
175:7746–7754. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sangro B, Galle PR, Kelley RK, Charoentum
C, De Toni EN, Ostapenko Y, Heo J, Cheng AL, Wilson Woods A, Gupta
C, et al: Patient-reported outcomes from the phase III HIMALAYA
study of tremelimumab plus durvalumab in unresectable
hepatocellular carcinoma. J Clin Oncol. 42:2790–2799. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cheng AL, Qin S, Ikeda M, Galle PR,
Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, et al:
Updated efficacy and safety data from IMbrave150: Atezolizumab plus
bevacizumab vs. sorafenib for unresectable hepatocellular
carcinoma. J Hepatol. 76:862–873. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xin Y, Zhang X, Liu N, Peng G, Huang X,
Cao X, Zhou X and Li X: Efficacy and safety of lenvatinib plus PD-1
inhibitor with or without transarterial chemoembolization in
unresectable hepatocellular carcinoma. Hepatol Int. 17:753–764.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Raoul JL, Forner A, Bolondi L, Cheung TT,
Kloeckner R and de Baere T: Updated use of TACE for hepatocellular
carcinoma treatment: How and when to use it based on clinical
evidence. Cancer Treat Rev. 72:28–36. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dawson LA, Winter KA, Knox JJ, Zhu AX,
Krishnan S, Guha C, Kachnic LA, Gillin MT, Hong TS, Craig TD, et
al: Stereotactic body radiotherapy vs sorafenib alone in
hepatocellular carcinoma: The NRG oncology/RTOG 1112 phase 3
randomized clinical trial. JAMA Oncol. 11:136–144. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vilgrain V, Pereira H, Assenat E, Guiu B,
Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W,
et al: Efficacy and safety of selective internal radiotherapy with
yttrium-90 resin microspheres compared with sorafenib in locally
advanced and inoperable hepatocellular carcinoma (SARAH): An
open-label randomised controlled phase 3 trial. Lancet Oncol.
18:1624–1636. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Garin E, Tselikas L, Guiu B, Chalaye J,
Edeline J, de Baere T, Assenat E, Tacher V, Robert C,
Terroir-Cassou-Mounat M, et al: Personalised versus standard
dosimetry approach of selective internal radiation therapy in
patients with locally advanced hepatocellular carcinoma
(DOSISPHERE-01): A randomised, multicentre, open-label phase 2
trial. Lancet Gastroenterol Hepatol. 6:17–29. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li
Q, Lu Y, Chen Y, Guo Y, et al: Sintilimab plus a bevacizumab
biosimilar (IBI305) versus sorafenib in unresectable hepatocellular
carcinoma (ORIENT-32): A randomised, open-label, phase 2–3 study.
Lancet Oncol. 22:977–990. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cai M, Huang W, Huang J, Shi W, Guo Y,
Liang L, Zhou J, Lin L, Cao B, Chen Y, et al: Transarterial
chemoembolization combined with lenvatinib plus PD-1 inhibitor for
advanced hepatocellular carcinoma: A retrospective cohort study.
Front Immunol. 13:8483872022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qiu G, Xie K, Jin Z, Jiang C, Liu H, Wan H
and Huang J: The multidisciplinary management of hepatocellular
carcinoma with portal vein tumor thrombus. Biosci Trends.
15:148–154. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang JD and Heimbach JK: New advances in
the diagnosis and management of hepatocellular carcinoma. BMJ.
371:m35442020. View Article : Google Scholar : PubMed/NCBI
|
